GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alseres Pharmaceuticals Inc (OTCPK:ALSE) » Definitions » Piotroski F-Score

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Piotroski F-Score : 0 (As of May. 22, 2024)


View and export this data going back to . Start your Free Trial

What is Alseres Pharmaceuticals Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Alseres Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Alseres Pharmaceuticals's Piotroski F-Score or its related term are showing as below:


Alseres Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for Alseres Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alseres Pharmaceuticals Piotroski F-Score Chart

Alseres Pharmaceuticals Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 3.00 4.00 5.00 3.00

Alseres Pharmaceuticals Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.00 3.00 3.00 4.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun14) TTM:Last Year (Jun13) TTM:
Net Income was -0.363 + 0.239 + -0.332 + -0.321 = $-0.78 Mil.
Cash Flow from Operations was -0.301 + -0.386 + -0.385 + -0.272 = $-1.34 Mil.
Revenue was 0.018 + 0.418 + 0.018 + 0.018 = $0.47 Mil.
Gross Profit was 0.018 + 0.418 + 0.018 + 0.018 = $0.47 Mil.
Average Total Assets from the begining of this year (Jun13)
to the end of this year (Jun14) was
(0.148 + 0.137 + 0.385 + 0.364 + 0.279) / 5 = $0.2626 Mil.
Total Assets at the begining of this year (Jun13) was $0.15 Mil.
Long-Term Debt & Capital Lease Obligation was $8.30 Mil.
Total Current Assets was $0.22 Mil.
Total Current Liabilities was $1.81 Mil.
Net Income was -0.572 + -0.459 + -0.298 + -0.52 = $-1.85 Mil.

Revenue was 0.012 + 0.018 + 0.018 + 0.018 = $0.07 Mil.
Gross Profit was 0.012 + 0.018 + 0.018 + 0.018 = $0.07 Mil.
Average Total Assets from the begining of last year (Jun12)
to the end of last year (Jun13) was
(0.13 + 1.02 + 0.966 + 0.354 + 0.148) / 5 = $0.5236 Mil.
Total Assets at the begining of last year (Jun12) was $0.13 Mil.
Long-Term Debt & Capital Lease Obligation was $16.00 Mil.
Total Current Assets was $0.09 Mil.
Total Current Liabilities was $9.83 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Alseres Pharmaceuticals's current Net Income (TTM) was -0.78. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Alseres Pharmaceuticals's current Cash Flow from Operations (TTM) was -1.34. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun13)
=-0.777/0.148
=-5.25

ROA (Last Year)=Net Income/Total Assets (Jun12)
=-1.849/0.13
=-14.22307692

Alseres Pharmaceuticals's return on assets of this year was -5.25. Alseres Pharmaceuticals's return on assets of last year was -14.22307692. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Alseres Pharmaceuticals's current Net Income (TTM) was -0.78. Alseres Pharmaceuticals's current Cash Flow from Operations (TTM) was -1.34. ==> -1.34 <= -0.78 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun14)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun13 to Jun14
=8.297/0.2626
=31.59558264

Gearing (Last Year: Jun13)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun12 to Jun13
=16/0.5236
=30.55767762

Alseres Pharmaceuticals's gearing of this year was 31.59558264. Alseres Pharmaceuticals's gearing of last year was 30.55767762. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun14)=Total Current Assets/Total Current Liabilities
=0.22/1.811
=0.12147985

Current Ratio (Last Year: Jun13)=Total Current Assets/Total Current Liabilities
=0.085/9.827
=0.00864964

Alseres Pharmaceuticals's current ratio of this year was 0.12147985. Alseres Pharmaceuticals's current ratio of last year was 0.00864964. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Alseres Pharmaceuticals's number of shares in issue this year was 0.006. Alseres Pharmaceuticals's number of shares in issue last year was 0.006. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.472/0.472
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.066/0.066
=1

Alseres Pharmaceuticals's gross margin of this year was 1. Alseres Pharmaceuticals's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun13)
=0.472/0.148
=3.18918919

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun12)
=0.066/0.13
=0.50769231

Alseres Pharmaceuticals's asset turnover of this year was 3.18918919. Alseres Pharmaceuticals's asset turnover of last year was 0.50769231. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+0+1+1+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Alseres Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Alseres Pharmaceuticals  (OTCPK:ALSE) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Alseres Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Alseres Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Alseres Pharmaceuticals (Alseres Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
275 Grove Street, Suite 2-400, Auburndale, MA, USA, 02466
Alseres Pharmaceuticals Inc is a US-based biotechnology company. It is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system. The company's lead product candidate is Altropane, a proprietary molecular imaging agent which is used to diagnose Parkinson's disease and dementia. Further, it is focused on entering into partnerships to ensure development and commercialization of its product. Geographically the firm carries out its business through the region of United States.
Executives
Mark Jerome Pykett officer: President and COO 223A MAIN ST, BOXFORD MA 021921
Robert Langer director 98 MONTVALE RD, NEWTON MA 02459
Peter G Savas director, officer: Chief Executive Officer 110 HARTWELL AVENUE, LEXINGTON MA 02173
John T Preston director C/O MOLTEN METAL TECHNOLOTY INC, 400-2 TOTTEN POND ROAD, WALTHAM MA 02154
Rice Kenneth L Jr officer: Exec VP of Fin & Admin & CFO C/O 85 MAIN STREET, HOPKINTON MA 01748
Joseph P Hernon officer: Chief Financial Officer 1607 PONCE DE LEON AVENUE, SUITE 407, SAN JUAN PR 00909
Stephen M Peck director P O BOX 554, 3600 S LAKE DRIVE, ST FRANCIS WI, MILWAUKEE WI 53201-0554

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Headlines